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ABSTRACT
Parkinson’s disease (PD) is a neurodegenerative disease, influencing 
mainly elderly. The key motor factor affecting the level of participation 
in activities of daily living is the gait function, which is known to be 
 progressively impaired in PD. However, gait characteristics also worsen 
due to normal aging. The main aim of this study was to investigate 
whether gait parameters decline in individuals with PD in an interval of 
one year compared to healthy elderly. Selected gait characteristics were 
recorded using 3-D optoelectronic movement analysis system ELITE in 
13 patients with mild-to-moderate PD and 13 age- and gender-matched 
controls. Hoehn and Yahr Scale and Unified Parkinson Disease Rating 
Scale were used for clinical assessment. It was found that PD patients 
walk with significantly shorter steps and stride and reduced gait speed. 
In one year, the stride length initiated with right foot and stride walk 
ratio  further decrease in PD patients. On re-evaluation the percentages 
of stance, swing and double support phase differed significantly between 
groups. In  second measurement, control subjects walked with reduced 
step width. It was concluded that gait speed and stride length decline 
in patients with PD in a period of one year, whereas no indication of 
 deterioration of gait function is evident in healthy controls.
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INTRODUCTION
Following Alzheimer’s disease, PD is the second most frequent neuro-
degenerative disease [16]. Generally, PD affects elderly – usual onset is 
between 50–70 years. Prevalence increases linearly until 80 years of age. 
About 2–3% of over 65-year olds are affected by this disorder [20].
Clinical features of PD result from degeneration of extrapyramidal sys-
tem [18]. The pathological findings show greatly diminished neurons in 
substantia nigra, resulting in several neurochemical changes that cause the 
disease-specific features of PD: rest tremor, rigidity and bradykinesia [24]. 
Symptoms of PD are mainly described through motor features, but various 
non-motor features are also typically seen. 
These impairments affect the overall motor performance and thus activi-
ties of daily living in patients with PD. Gait disturbances are one of the most 
disabling symptoms of PD and they contribute to person’s performance in 
activities of daily living and through this reduce the quality of life [10]. In 
PD, spatiotemporal parameters of gait deteriorate significantly when the 
dose of the medication decreases, but also at peak dose patients walk with 
shorter steps and slower walking speed than control subjects [129. Latter 
indicates that mobility deficits are difficult to treat with merely antipar-
kinsonian drugs. Therefore, referral to physiotherapy in this contingent of 
patients is recommended highly from very beginning of the disease. The 
role of physiotherapy is to teach patients with PD compensatory strategies 
for coping with their impairments, to improve their functional performance 
and avoid secondary complications due to inactivity and thereby prolonging 
the period of independency for the patient and preserve the quality of life for 
maximally long period [8]. 
Physiotherapists also play a role in assessing the ability of people with 
PD to accomplish complex tasks and assess changes in function, disability, 
 activity, and response to therapy, as well to monitor the natural progres-
sion of the disease [2]. The analysis of annual change in spatiotemporal 
gait parameters could provide physiotherapists with objective data. The 
main aim of this study was to investigate whether gait parameters decline 
in individuals with mild-to-moderate PD present in an interval of one year 
different from healthy age- and gender-matched counterparts. Although 
our study included laboratory assessment of selected gait parameters, the 
spatio temporal gait analysis was chosen because it is possible to perform the 
assessment similarly in clinical setting and in home environment. 
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MATERIALS AND METHODS
Subjects
Participants with PD were recruited from the Department of Neurology, 
Tartu University Hospital. All of them were living in community. Patients 
aged under 80, and with disease severity according to modified Hoehn and 
Yahr (HY) currently in stages 2.0–3.0, not diagnosed with other neurologi-
cal conditions and not presenting acute medical problems and conditions 
affecting mobility were contacted at their scheduled neurologist appoint-
ment. Absence of severe dyskinesia and long “off ”-periods was also an inclu-
sion criterion, as well as not requiring an assistive device for indoor mobility. 
A convenience sample of 13 patients was enrolled and it included six female 
and seven male participants with idiopathic PD. Age- and gender-matched 
healthy control group was recruited with the help of one local family doctor 
confirming them to be free of any possible limiting health conditions. 
The study was approved by the Ethics Committee of University of Tartu 
and all participants signed an informed consent declaration. General clinical 
and demographic characteristics of the participants are presented in Table 1. 
Table 1. Comparison of clinical and demographic characteristics of the participants at 
baseline
Variable
Participants with 
PD (n=13)
Controlgroup 
(n=13) p value
Age (years) 65.2±6.7 64.9 ±7.0 0.90
Disease duration (years) 8.7±5.5 NA –
HY stage 2.3±0.5 NA –
UPDRS total score 62.4±19.6 NA –
Height (m) 1.7±0.1 1.7±0.1 0.83
Weight (kg) 71.3±16.9 73.9±13.3 0.51
Note: PD – Parkinson disease; NA – not applicable; HY – Hoehn &Yahr Scale; UPDRS – Uni-
fied Parkinson Disease Rating Scale. 
Procedures
Objective testing was conducted in the Laboratory of Kinesiology and 
Biomechanics of Tartu University and clinical examination of the patients 
occurred within few hours in the Tartu University Hospital. Both patients 
and controls were tested twice – at baseline and approximately 1 year later. 
All the participants had an adequate comprehension of instructions. 
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Participants with PD were medicated with ordinary anti-parkinsonian 
drugs and were tested in a self-diagnosed “on-phase” of medication. Current 
stage of PD was recorded by qualified neurologist using HY and Unified 
Parkinson’s Disease Rating Scale (UPDRS). The UPDRS was designed to 
follow the longitudinal course of the disease and has been shown to be both 
reliable and valid [1]. It has four parts (subscales), comprising symptoms of 
mentation, behaviour, and mood in part I, activities of daily living in part II, 
motor symptoms in part III, and complications of therapy in part IV. Each 
item in part I to III is quantitatively scored on a 5-point scale (from 0 to 4) 
[2]. The result of the UPDRS can be interpreted as higher the result of the 
UPDRS, the more expressed is the Parkinson’s disease of the patient. During 
the assessment, only patient and neurologist were in the room. 
The assessment for anthropometrical parameters and was conducted in 
same manner for both groups. First, the anthropometrical parameters were 
registered (participants wearing light well-fitting clothing). Thereafter, for 
gait analysis 20 reflective markers were fixed on anatomical landmarks of 
the subject, according to the Davies protocol. Six infrared cameras and a 
3-D optoelectronic movement analysis system ELITE (BTS Bioengineer-
ing, Milan, Italy) registered the displacement of 20 reflective markers fixed 
on anatomical landmarks of the subject. The instructions given to the sub-
jects were following: “Walk with your normal walking speed to the end of 
the walkway.” Practice trial preceded data collection. For data analysis the 
performance of barefoot gait on 6-meter-walkway (Kistler, Switzerland) at 
self-selected speed was recorded and average of 3 trials was used for data 
analysis. 
Selected gait characteristics obtained with the 3-D gait analysis were used 
for data analysis. The parameters (measurement units presented in paren-
thesis) were following: step length (mm); stride length (mm); cadence (steps 
per min); mean velocity of gait (m/s); step width (mm); stance and swing 
phase percentage of the gait cycle (%); double support phase percentage of 
the gait cycle (%). Step and stride length of both lower limbs are presented, 
for other parameters only the average of left and right side is presented. 
Ducharme et al. [5] suggested that walk ratio (step length divided to 
cadence) could be used to discriminate between healthy and disabled indi-
viduals. In Kirtlet’s [9] overview of the temporal-spatial parameters, the walk 
ratio is mentioned and is calculated as stride length divided by cadence. In 
present study we calculated walk ratio using both methods, naming them 
step walk ratio and stride walk ratio, respectively (using average step and 
stride length). 
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Statistical Analysis
Analysis was performed using SPSS 20.0. Descriptive analysis was per-
formed. The Wilcoxon Signed Ranks test or Mann–Whitney U-test were 
used to compare groups. The effect size was calculated based on the coef-
ficient of the product-moment correlation (r) [26]. The coefficient of the 
product-moment correlation was chosen to allow comparison between para-
metric and non-parametric data. A level of significance p<0.05 was selected 
to indicate statistical significance.
RESULTS
Results are summarized in Table 2. Patients with PD walked with signifi-
cantly (p<0.05) shorter steps and strides and reduced gait speed compared to 
controls at both measurements. The step walk ratio and stride walk ratio and 
the percentage of stance, swing and double support phase was also different 
between groups during re-evaluation one year later. 
When looking at within-group differences it can be concluded that gait 
parameters did not change markedly during one year at either group. In PD 
group, merely stride walk ratio and stride length initiated with right foot 
deteriorated at significant extent. Control group demonstrated reduced step 
width during re-evaluation. 
When looking at clinical assessment results of PD presentation, a 
 significant change was evident merely in the UPDRS active daily living 
score (p=0.01), whereas the UPDRS motor score (nearly significant, p=0.06) 
and he UPDRS total score nor HY did not indicate more severe disease 
 presentation. 
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DISCUSSION
Disturbances in spatiotemporal parameters of gait are well documented in 
patients with PD [3, 7, 12, 19, 21]. Though there are numerous data that also 
gait kinematics and kinetics are altered by PD [10, 25], it was not of inter-
est to analyse these parameters in the present study. Present study aimed to 
illustrate the differences in decline of selected spatiotemporal parameters of 
gait in patients with PD and age- and gender-matched controls in an interval 
of one year that has not been described in the follow-up before.
In the present study, consistent with previous findings [10, 14, 25], PD 
patients demonstrated a gait pattern with shorter step (and stride) and 
smaller walking velocity at baseline compared to control subjects. 
PD patients demonstrated shorter stride length (by ~13%) and reduced 
mean velocity than healthy controls. Other authors have reported more 
pronounced differences between controls and PD patients – for example 
Lewis et al. [10] found 24% reduction in gait velocity and 23% reduction in 
stride length. This is probably due more severe disease (2.8 at HY scale for 
the study of Lewis et al. compared to 2.6 for the present study) and longer 
 disease duration (9.1±5.7 vs 8.2±3.9 years). Another aspect might be related 
to the control group – though we were assured by the family doctor that 
helped with recruiting the control group that the subjects were currently 
healthy and free of possible limitations, they still had some health restric-
tions, possibly somewhat influencing the result. The step walk ratio in the 
present study was 6.0 mm/(step/min) – this result stays below walk ratio 
considered to be constant for healthy adults (6.5 mm/(step/min) [19]. 
However, as suggested by Ducharme et al. [5], participants with PD and 
healthy counterparts could be distinguished by walk ratio during re-evalua-
tion: both step and stride walk ratio differed between groups. However, stride 
walk ratio was also one of the parameters that demonstrated distinct deterio-
ration within-patient group, indicating it to be possible a slightly more sensi-
tive parameter than step walk ratio to demonstrate decline in gait function of 
individuals with PD. Smaller walk ratio has been found to be associated with 
falling in community-dwelling elderly [15], so it seems highly favourable to 
use this parameter for gait assessment also in clinical setting. 
In agreement with previous findings [12, 14], the cadence was similar in 
both measurements in PD patients and the controls. Some studies [17, 19] 
have suggested that patients with PD have higher cadence to compensate 
the reduced stride length. Nieuwboer et al. [17] reported an exponential 
increase of cadence with a decreasing stride length during freezing. The 
cadence also increased in the present study for one year, but the change was 
not significant. 
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Reduced stride length is considered the most characteristic feature of 
parkinsonian gait. Often it is accompanied with reduced walking speed and 
tendency toward longer double-support phase duration [14]. It has been 
suggested, that the increased percentage of double support phase in PD is 
directly related with levodopa concentration in organism – the lower con-
centration relates to the longer double support phase [17]. It is possible that 
because of experiencing postural instability, patients compensate this by 
increasing the time in which both feet are in contact with the ground [13]. 
Differences in double support phase in present study reached significant 
level by the re-evaluation. 
Canning et al. [3] showed that when PD patients are able to walk at 
 velocities comparable to healthy controls, they do not sustain this  velocity 
over longer distances. It is possible that this is the reason for relatively 
unchanged gait speed in present study.
Studies have shown that the gait characteristics (speed, stride length) of 
PD patients can be improved significantly by the use of appropriate influ-
ences [25], for example external stimuli and didactic methods. It has been 
found that by simply asking PD patient to walk with longer steps, they can 
significantly increase the walking speed and amplitude within normal  values, 
which can last for up to 2 hours [17]. Patients with PD typically rely on 
external cues for locomotion. On the walkway used in present study, there 
were two small dots of blue coloured stripe, and the walkway ended with 
a perpendicular yellow stripe. These were there for the purposes of other, 
routinely performed measurements in this laboratory. It is known that PD 
patients are able to improve their ambulation when auditory, tactile, cogni-
tive or visual cues are given [22]. It may be that the coloured dots and stripe 
and the apparatus of the laboratory might have served as a visual stimulus 
for the patients and to improve their gait parameters at some extent. 
Charlett et al. [4] showed that step width increases early in the  disease, 
to compensate for altered balance and posture, and it narrows later in 
the  disease. In the present study, step width of PD participants did not 
change, however, it decreased during one year in the control group – prob-
ably because they were more familiar and comfortable with the analysis 
 procedure. 
After one year, a significantly different stride length initiated with the 
right foot was observed in PD patients. This is probably explainable by 
higher gait variability (especially stride-to-stride variability) characteristic 
to PD gait according to [7]. 
The main limitation of our study was relatively small study sample. How-
ever, we believe interpretation of the study results has been conservative 
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and the conclusion we have made relay on reliable data analysis. Further, 
behavioural aspects such as fear of falling also contribute to gait parameters. 
Comorbid depression, very common in PD [11] causes slowing the walk-
ing speed [21]. Unfortunately, these aspects were not covered thoroughly in 
present study, as well as presence of freezing of gait etc. In addition, it may 
be argued that subjects should have been assessed a certain time after taking 
their antiparkinsonian medication. Mainly for logistical reasons, the patients 
were tested in self-diagnosed “on-phase” of medication. Most studies have 
used assessment in both off-phase and on-phase. 
In the clinical characteristic’s significant differences between baseline 
and one year later were seen merely in UPDRS active daily living score, 
although total score also indicated nearly significant deterioration (p=0.06). 
This supports the findings from Frysinger et al. [6], who indicated that active 
daily living score serves as a better marker of disease progression than other 
 sections of the UPDRS.
In conclusion, despite some limitations, present study demonstrated 
the different rates of decline of gait parameters during one-year period in 
patients with PD and healthy controls with sufficient credibility. In accord-
ance with previous studies, patients with mild-to-moderate PD walk with 
significantly shorter step and stride length and reduced mean velocity of the 
gait, compared with age- and gender-matched control subjects. Following 
one-year period, stride length initiated with right foot and stride walk ratio 
significantly deteriorate in patients’ group. 
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